Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma

Table 1

Clinical studies investigating immunotherapy in ACC.

Drug	Target	Study phase	Patients	Results	Ref.
Avelumab	PD-L1	I	50	ORR: 6%; OS: 10.6 months; PFS: 2.6	[16]
Ipilimumab; +; radiotherapy	CTLA-4	I/II	Active, nonrecruiting	-	NCT02239900
Pembrolizumab	PD-L1	II	Recruiting	-	NCT02673333
Nivolumab; +; ipilimumab	PD-1/; CTLA4	II	Recruiting	-	NCT03333616

ORR: overall response rate; OS: overall survival; PFS: progression-free survival.